Glenmark’s US Alliance Ichnos Glenmark Innovation to Present Phase 1 Data of ISB 2001

Ichnos Glenmark Innovation (IGI), a collaboration between Ichnos Sciences Inc. and Glenmark Pharmaceuticals Ltd., announced that it will present first-time data from its Phase 1 study of ISB 2001 at the 66th American Society of Hematology (ASH) Annual Meeting in San Diego, California. ISB 2001 is IGI’s first-in-class tri-specific antibody, designed to target BCMA and CD38 on myeloma cells and CD3 on T cells. The antibody is currently being investigated in relapsed/refractory multiple myeloma (r/r MM).

The oral presentation at ASH will focus on results from the dose-escalation portion of the Phase 1 study. The abstract, based on data as of July 2024, highlights an overall response rate (ORR) of 75% (9/12) in efficacy-evaluable patients. Notably, one patient achieved a stringent complete response (sCR) with minimal residual disease (MRD) negativity.

The study also demonstrated a favourable safety and tolerability profile. Importantly, there were no dose-limiting toxicities (DLTs) observed. The only adverse event of special interest (AE) was above Grade 2, and there were no treatment discontinuations reported.

“Although recent advancements have brought new therapeutic options to multiple myeloma patients, resistance mechanisms continue to limit their efficacy, necessitating multiple lines of treatment for many patients,” said Lida Pacaud, M.D., Chief Medical Officer at IGI. “We are encouraged by the early data from our Phase 1 study of ISB 2001, which shows a remarkable response rate and demonstrates the potential to address these challenges in heavily pretreated patients.”

About Ichnos Glenmark Innovation

Ichnos Glenmark Innovation (IGI) is an alliance between Ichnos Sciences Inc., a global fully integrated clinical-stage biotech company developing multispecifics™ in oncology, and

Glenmark Pharmaceuticals Ltd. (Glenmark), to accelerate new drug discovery in

cancer treatment. 

About Glenmark Pharmaceuticals Ltd

Glenmark Pharmaceuticals Ltd is a global research-led pharmaceutical company with a presence across generics, Specialty and OTC business with operations in over 80 countries.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. It is based on several secondary sources on the internet and is subject to changes. Please consult an expert before making related decisions.